News for Healthier Living

Enhanced CAR T Cell Therapy Offers New Strategy for Lymphoma

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. The findings, led by researchers in the Perelman School of Medicine at the University of Pennsylvania, were published today in the New England Journal of Medicine.

May 7, 2025


May 15 2025

May 14 2025

May 13 2025

May 12 2025

May 11 2025

May 10 2025

May 9 2025

May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025